RhumbLine Advisers’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

RhumbLine Advisers’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-4,540	Closed	-$15K	–	2990
2017 Q1	$15K	Buy	4,540 +230	+5%	+$1.09K	﹤0.01%	2841
2016 Q4	$22K	Sell	4,310 -2,777	-39%	-$48.1K	﹤0.01%	2842
2016 Q3	$179K	Buy	7,087 +38	+0.5%	+$958	﹤0.01%	2713
2016 Q2	$174K	Buy	7,049 +2,267	+47%	+$64K	﹤0.01%	2803
2016 Q1	$138K	Buy	4,782 +13	+0.3%	+$353	﹤0.01%	2838
2015 Q4	$177K	Buy	4,769 +457	+11%	+$20.2K	﹤0.01%	2836
2015 Q3	$210K	Buy	4,312 +478	+12%	+$33.4K	﹤0.01%	2764
2015 Q2	$264K	Buy	+3,834	New	+$177K	﹤0.01%	2745

Other funds holding ANTH

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

RhumbLine Advisers's ANTH Position: Q2 2017 in Review

RhumbLine Advisers sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2017, closing a stake of 4,540 shares — an estimated $15K sold.

RhumbLine Advisers first reported a position in ANTH in Q2 2015 and held it in 8 quarters. The position peaked at $264K in Q2 2015. 40 funds tracked by Wall St. Rank hold ANTH as of Q2 2017.

RhumbLine Advisers reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
RhumbLine Advisers sold 4,540 Anthera Pharmaceuticals, Inc. shares in Q2 2017, an estimated $15K.
RhumbLine Advisers first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2015 and held it in 8 quarters.
RhumbLine Advisers's Anthera Pharmaceuticals, Inc. position peaked at $264K in Q2 2015.
40 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2017.

Based on RhumbLine Advisers's 13F filing for Q2 2017, filed 2 Aug 2017.